Drug class
Hepatitis C virus (HCV) NS3/4A serine protease inhibitor; direct-acting antiviral
Mechanism of action
Reversibly binds the active centre of the HCV NS3/4A protease and prevents protease-mediated cleavage of the viral polyprotein, disrupting maturation of viral proteins needed for replication. It is used in combination regimens; ritonavir increases paritaprevir exposure through CYP3A4 inhibition.
General use cases
- Used only as part of labelled combination regimens for chronic hepatitis C, such as ombitasvir/paritaprevir/ritonavir with or without dasabuvir; indication and availability are regimen- and jurisdiction-specific.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
